VTIV inVentiv Health, Inc. featured news, full reports, and detailed charts
inVentiv Health, Inc. (VTIV) Wrap Up:
inVentiv Health Inc. (together with its subsidiaries, “inVentiv”, or the “Company”) is a leading provider of value-added services to the pharmaceutical, life sciences and healthcare industries. We support a broad range of clinical development, communications and commercialization activities that are critical to our customers' ability to complete the development of new drug products and medical devices and successfully commercialize them. In addition, we provide medical cost containment services to payors in our patient outcomes business. Our goal is to assist our customers in meeting their objectives by providing our services in each of our operational areas on a flexible and cost-effective basis. We provide services to over 325 client organizations, including all top 20 global pharmaceutical companies, numerous emerging and specialty biotechnology companies and payors. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f29%2f0001089473-08-000014.html#FIS_BUSINESS"www.inventivhealth.com
7,100 Employees
Founded in 1997
inVentiv Health, Inc. (VTIV:NASDAQ)
LAST $16.10 USD
CHANGE TODAY -0.11 -0.68%
VOLUME 246.3K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of inVentiv Health, Inc. (VTIV)
|
OPEN
$16.07
|
PREVIOUS CLOSE
$16.21
|
|
|
DAY HIGH
$16.28
|
DAY LOW
$15.97
|
|
|
52 WEEK HIGH
10/21/09 - $18.97
|
52 WEEK LOW
03/10/09 - $6.60
|
|
|
MARKET CAP
540.9M
|
AVERAGE VOLUME 3 mo
167.3K
|
|
|
DILUTED EPS TTM
$-3.99
|
SHARES OUTSTANDING
33.6M
|
|
|
VTIV Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
InVentiv Health Companies Win Seven CLIO Healthcare Awards
Investrend - 11/18/2009 11:28 AM ET
VTIV Top Compensated Officers
Mr. R. Blane Walter
Chief Executive Officer and Director
Total Annual Compensation: $797.1K
Mr. Terrell Herring
President, Chief Operating Officer, Director,...
Age: 45
Total Annual Compensation: $570.3K
Mr. Eran Broshy
Executive Chairman
Age: 50
Total Annual Compensation: $440.7K
Mr. David S. Bassin
Chief Financial Officer, Principal Accounting...
Age: 37
Total Annual Compensation: $389.8K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for inVentiv Health, Inc. (VTIV)
inVentiv Health, Inc. Announces Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2009 ; Provides Earnings Guidance for the Fourth Quarter of 2009 ; Announces Resignation of Terry Herring as President and Chief Operating Officer, Effective December 31, 2009
11/5/2009
inVentiv Health, Inc. announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. Total revenues decreased 6% to $270.5 million for the third quarter of 2009, compared to $289.2 million for the third quarter of 2008. Adjusted EBITDA decreased 12% to $32.6 million for the third quarter of 2009, compared to $37.2 million for the third quarter of 2008. Adjusted operating income decreased 13% to $24.3 million for the third quarter of 2009, compared to $27.8 million for the third quarter of 2008. GAAP operating income was $24.6 million for the third quarter of 2009, compared to $27.6 million for the third quarter of 2008. Adjusted Net income attributable to inVentiv Health, Inc. was $11.5 million for the third quarter of 2009, compared to adjusted net income of $13.6 million for the third quarter of 2008. Net income attributable to inVentiv Health, Inc., was $11.7 million for the third quarter of 2009, compared to $13.3 million for the third quarter of 2008. Adjusted diluted earnings per share (EPS) attributable to inVentiv Health, Inc. was $0.34 for the third quarter of 2009 and GAAP diluted EPS was $0.35, compared to an adjusted diluted EPS of $0.41 for the third quarter of 2008 and GAAP diluted EPS of $0.40 for the third quarter of 2008. The company also generated $20.9 million of cash flow from continuing operations for the quarter. Income from continuing operations of $11.8 million or $0.35 per diluted share compared to income from continuing operations of $13.4 million or $0.40 per diluted share for the same period of last year. For the nine months, the company reported income from continuing operations of $31.0 million or $0.92 per diluted share compared to income from continuing operations of $35.4 million or $1.03 per diluted share for the same period of last year. The company reported operating income of $68.7 million and net income attributable to the company of $30.9 million or $0.92 per diluted share on total revenues of $797.1 million compared to operating income of $75.4 million and net income attributable to the company of $34.5 million or $1.03 per diluted share on total revenues of $836.5 million for the same period of last year. The company also generated $78.7 million of cash flow from continuing operations for nine months of 2009. The company is providing a fourth quarter 2009 revenue target range of $270 million to $285 million and earnings per share target range of $0.40 to $0.43. The company announced that Terry Herring, president and chief operating officer will resign his position effective December 31, 2009.
Star Scientific, Inc. Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health, Inc.
11/4/2009
Star Scientific, Inc. announced that the company plans to introduce the CigRx(TM) nutraceutical product developed by its subsidiary, Rock Creek Pharmaceuticals, for worldwide marketing and sales in partnership with inVentiv Health, Inc. inVentiv Health offers a complete range of commercialization solutions for every stage of the product lifecycle, in a range of healthcare categories that includes nutraceutical products. The company has marketing and sales capabilities in 40 countries around the globe.
inVentiv Health, Inc. - Conference Presentation Call
11/2/2009
inVentiv Health, Inc. - Conference Presentation Calls
VTIV Competitors
| Company | Last | Change |
| America Service Group Inc | $14.01 USD | +0.33 |
| Cross Country Healthcare Inc | $8.67 USD | +0.07 |
| Heidrick & Struggles International Inc | $28.54 USD | -0.24 |
| Kforce Inc | $13.49 USD | -0.11 |
| Korn Ferry Intl | $16.30 USD | -0.13 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | VTIV | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.5x |
|
| Price/Book | 1.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.1x |
|
|
VTIV |
||
|
VTIV transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About inVentiv Health, Inc.
More news for VTIV
Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health
PETERSBURG, Va., Nov. 4 /PRNewswire-FirstCall/ -- Star Scientific, Inc. (Nasdaq: STSI - News) announced today that the company plans to introduce the CigRx(TM) nutraceutical product developed by its subsidiary, Rock Creek Pharmaceuticals, for worldwide marketing and sales in partnership with inVentiv Health, Inc. (Nasdaq: VTIV - News). inVentiv Health offers a complete range of commercialization solutions for every stage of the product lifecycle, in a range of healthcare categories that includes nutraceutical products. The company has marketing and sales capabilities in 40 countries around the globe. Jonnie R. Williams, Star's CEO, stated, "Cigarette smoking is the leading cause of preventable death in the world. However, the global cigarette business, which now exceeds $300 billion, continues to grow. Our goal is to make CigRx(TM) available to adult smokers worldwide who wish to maintain a nico...Click here to read the whole Article (external link)
inVentiv Health to Present at 18th Annual Credit Suisse Healthcare Conference
inVentiv Health to Present at 18th Annual Credit Suisse Healthcare Conference - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: l...Click here to read the whole Article (external link)
inVentiv Health Reports Financial Results for Third Quarter 2009
* Third Quarter Revenues declined 6% to $270.5 mm * Third Quarter Adjusted EPS $0.34 (GAAP EPS $0.35) * President/COO Resigns SOMERSET, N.J., Nov. 4, 2009 (GLOBE NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV - News), a leading provider of commercialization services to the global pharmaceutical and healthcare industries, today announced financial results for the third quarter 2009. Third Quarter 2009 Results attributable to inVentiv Health, Inc.: * Total revenues decreased 6% to $270.5 million for the third quarter of 2009, compared to $289.2 million for the third quarter of 2008. Net revenues declined 4% to $232.8 million, compared to $243.4 million for the third quarter of 2008. * Adjusted EBITDA decreased 12% to $32.6 million for the third quarter of 2009, compared to $37.2 million for the third quarter of 2008. Adjusted Operating income decreased 13% to $24.3 million for the third quarter of 2009, compared to $27.8 million for the third quarter of 2008. GAAP operating income was $24.6 million for the third quarter of 2009, compared to $27.6 million for the third quarter of 2008. * Adjusted Net income attributable to inVentiv Health, Inc. was $11.5 million for the third quarter of 2009, compared to adjusted net income of $13.6 million for the third quarter of 2008. Net income attributable to inVentiv Health, Inc., as reported was $11.7 million for the third quarter of 2009, compared to $13.3 million for the third quarter ...Click here to read the whole Article (external link)
inVentiv Health Announces Terrell Herring to Resign
SOMERSET, N.J., Nov. 4, 2009 (GLOBE NEWSWIRE) -- inVentiv Health (Nasdaq:VTIV - News) announced today that Terrell Herring will resign as President and Chief Operating Officer (COO) of inVentiv Health effective December 31, 2009, and join Mission Pharmacal, a growing Texas-based manufacturer of prescription drug products and nutritionals, as President of its Pharmaceutical division. Mission Pharmacal has been an inVentiv client since 2001. "I am very happy for Terry and wish him great success in his new role with Mission Pharmacal," said Blane Walter, Chief Executive Officer of inVentiv Health. "Over the past 10 years, Terry has helped inVentiv become a formidable competitor. He also has played a critical role in guiding the organization to become more integrated and operationally efficient. I am pleased that Terry will continue to work with us as a client, and that inVentiv will further strengthen our long-standing relationship with Mission Pharmacal under his leadership." Mr. Herring joined inVentiv Health in 1999 as a National Business Director and, after several promotions, he went on to lead the company's largest division, inVentiv Commercial, as President and CEO. In 2006, he was appointed to inVentiv Health's Board of Directors, and was named President and COO of inVentiv Health in 2008. Mr. Herring will transition to his new role at Mission Pharmacal in January 2010. He will continue in his position as a Director on inVentiv's Board of Directors. About inVentiv Health ...Click here to read the whole Article (external link)
Q3 2009 inVentiv Health, Inc. Earnings Release - Time Not Supplied
Earnings Announcements for Thursday, November 5CompanySymbolTimeConferenceCall21st Century HoldingTCHC2:00 pm ET3I INFRASTRUCTURE3IN.LBefore Market OpenAbiomed, Inc.ABMDBefore Market OpenListenABOVENET INCABVTAfter Market CloseListenAbraxis BioScience, Inc.ABIIBefore Market OpenListenAccelrys Inc.ACCLAfter Market CloseListenACI Worldwide, Inc.ACIWBefore Market OpenACTIONS SEMICONDUCTOR CO LTDACTSAfter Market CloseActive Biotech ABACTI.STTime Not SuppliedActivision Blizzard, Inc.ATVIAfter Market CloseAdecco SAAHEXF.PK01:00 am ETAinsworth Lumber Company Ltd.ANS.TOAfter Market CloseAir MethodsAIRMAfter Market CloseAker ASAAKERTime Not SuppliedALAMOS GOLD INCAGI.TOBefore Market OpenAlaska Communications Systems GroupALSKAfter Market CloseAlexandria Real Estate...Click here to read the whole Article (external link)
New Star Analyst Rankings for inVentiv Health, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
INVENTIV HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fina
Item 2.02. Results of Operations and Financial Condition. On November 4, 2009, inVentiv Health, Inc. (the "Company"), issued a press release announcing its financial results for the three months ended September 30, 2009. A copy of the Company's press release is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference. The non-GAAP financial measures "adjusted net income" and "adjusted diluted EPS" discussed in the press release are related to the following two factors: · Derivative Interest: In October 2005, the Company engaged in an interest rate hedge of its $175 million term loan facility, which the Company did not designate for hedge accounting until July 2006. In July 2006, the Company employed a hypothetical derivative model to assess ineffectiveness. For the three-months ended September 30, 2008, the Company recorded $0.3 million of interest expense (approximately $0.2 million, net of taxes), relating to the ineffectiveness of the hedge for the quarter. Net interest expense was adjusted to exclude these adjustments in the third quarter of 2008. Starting in 2009, there is no ineffectiveness in the Company's interest rate hedge. · Other than Temporary Gain/Impairment on Marketable Securities: During the third quarter of 2009 and 2008, the Company recorded an approximately $0.3 million gain ($0.2 million net of taxes) and an approximately $0.2 million ($0.1 million net of taxes) impairment, respectively, related to an other than temporary gain/impairment of the Company's Columbia Strategic Cash Portfolio ("CSCP"), which held certain asset-backed securities. Consistent with the company's investment policy guidelines, the vast majority of holdings within CSCP held by the company had AAA/Aaa credit ratings at the time of purchase. With the liquidity issues experienced in the global credit and capital markets, the CSCP experienced other than temporary losses resulting in a change in the net asset value per sha...Click here to read the whole Article (external link)
inVentiv Health Companies Win Seven CLIO Healthcare Awards
SOMERSET, N.J., Nov. 17, 2009 (GLOBE NEWSWIRE) -- inVentiv Health (Nasdaq:VTIV - News) is pleased to announce that four of its companies recently won top honors at the first-ever 2009 CLIO Healthcare Awards, an extension of The CLIO Awards, one of the world's most recognized award competitions for advertising, design and interactive. The awards were announced on November 13 in New York City. inVentiv Health companies took home more CLIO awards than any other advertising agency network. GSW Worldwide was honored with two silver awards in the Direct to Consumer Disease Awareness print category for their work with Takeda's Uloric for 'Flares Aren't the Whole Story,' and 'A (Slightly Confusing) History of Eczema' for Astellas' Protopic. The agency also took home silver for Covidien's 'Dosing Matters' in the Direct to Professional (DTP) print category. The agency's work for Ethicon Endo-Surgery, Inc's 'Ligamax 5- Test Center' was named a finalist in the DTP device and diagnostics category. Pink Tank, a specialty division of GSW Worldwide that focuses on women and health, was awarded bronze for their corporate self-promotion print campaign. The division's website, www.knowher.com, was re...Click here to read the whole Article (external link)
INVENTIV HEALTH INC Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue270,465 269,041 257,652 283,276 Cost of Revenue184,323 182,276 181,176 192,358 Gross Profit86,142 86,765 76,476 90,918 Operating ExpensesResearch Development - - - - Selling General and Administrative61,588 61,917 57,154 60,701 Non Recurring - - - 267,849 Others - - - - Total Operating Expenses - - - - Operating Income or Loss24,554 24,848 19,322 (237,632)Income from Continuing OperationsTotal Other Income/Expenses Net15 50 65 299 Earnings Before Interest And Taxes24,569 24,898 19,387 (237,333)Interest Expense5,775 5,773 5,774 6,330 Income Before Tax18,794 19,125 13,613 (243,663)Income Tax Expense6,863 7,768 5,772 (80,725)Minority Interest(140) - - (124)Net Income From Continuing Ops11,858 11,348 7,858 (163,117)Non-recurring EventsDiscontinued Operations - - - (104)Extraordinary Items - - - - Effect Of Accounting Changes - &n...Click here to read the whole Article (external link)
INVENTIV HEALTH INC Files SEC form 10-Q, Quarterly Report
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the consolidated financial statements, accompanying notes and other financial information included herein and in our Annual Report on Form 10-K for the year ended December 31, 2008. Overview inVentiv Health Inc. (together with its subsidiaries, "inVentiv", "we", "us" or "our") is a leading provider of value-added services to the pharmaceutical, life sciences and healthcare industries. We support a broad range of clinical development, communications and commercialization activities that are critical to our customers' ability to complete the development of new drug products and medical devices and successfully commercialize them. In addition, we provide medical cost containment services to payors in our patient outcomes business. Our goal is to assist our customers in meeting their objectives by providing our services in each of our operational areas on a flexible and cost-effective basis. We provide services to over 350 client organizations, including all top 20 global pharmaceutical companies, numerous emerging and specialty biotechnology companies and third party administrators. Our service offerings reflect the changing needs of our clients as their products move through the late-stage development and regulatory approval processes and into product launch and then throughout the product lifecycle. We have established expertise and leadership in providing the services our clients require at each of these stages of product development and commercialization and seek to address their outsourced service needs on a comprehensive basis throughout the product life cycle. For payors, the Company provides a variety of services that enhance savings and improve patient outcomes including opportunities to...Click here to read the whole Article (external link)
Would you like to leave a comment about inVentiv Health, Inc. VTIV
Find out what social network information about inVentiv Health, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides inVentiv Health, Inc. there is more great information available at Realpennies.com